Market Cap: $2.16B
PI
Precigen, Inc.
PGEN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $2.16B
Precigen Inc. (Ticker: PGEN) is making significant strides in the biopharmaceutical landscape with the recent approval of orphan drug exclusivity for its therapy, PAPZIMEOS. This key decision by the F…
Precigen (Ticker: PGEN) achieves a critical milestone with the recent announcement that its drug PAPZIMEOS has received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the…
Precigen (Ticker: PGEN) secures orphan drug exclusivity for PAPZIMEOS, expanding its foothold in the biotech sector. This significant milestone demonstrates the company's commitment to addressing unme…
On June 11, 2026, Precigen, Inc. (Ticker: PGEN) joins forces with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to acknowledge the third annual International RRP Awareness Day. This obser…
Precigen (Ticker: PGEN) secures a vital milestone in the treatment of recurrent respiratory papillomatosis (RRP) with FDA approval for its therapy PAPZIMEOS™. This development marks a significant adva…
In early April 2026, Precigen Inc. announces its expectations for first-quarter sales of its respiratory therapy, PAPZIMEOS, projected to exceed US$18 million. This optimistic forecast comes on the he…
Precigen Advances in Immunology: New Strategies for Treating Respiratory Papillomatosis In a notable development for the biopharmaceutical landscape, Precigen, Inc. reveals its focus on addressing sub…
Precigen Advances Regulatory Approvals in Cancer Therapies Precigen, Inc., a biopharmaceutical company focused on innovative therapeutic solutions, is making notable strides in the fight against cance…
Precigen Achieves Milestone with FDA Approval of PAPZIMEOS Precigen, Inc. makes significant strides in the biopharmaceutical sector with the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba), m…
Precigen Achieves Milestone with FDA Approval of PAPZIMEOS for RRP Treatment Precigen, Inc. has reached a pivotal milestone with the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba), marking i…
Ultragenyx Faces Challenges Amidst Market Volatility Ultragenyx Pharmaceutical Inc. is currently navigating a turbulent period marked by a significant decline in its stock performance. The downturn re…
Precigen's Innovative Approach to Gene Therapy: A New Frontier in Biotechnology Precigen, a pioneering biotechnology company, is making significant strides in the field of gene therapy, focusing on de…
Precigen Advances in Gene Therapy Amid Market Uncertainty In a landscape characterized by market volatility and investor caution, Precigen stands at the forefront of innovation in gene therapy. The co…
Precigen's Innovative Therapeutics: A Beacon Amid Economic Uncertainty In the face of turbulent stock market conditions, where the Nasdaq Composite sees declines and investor sentiment remains bearish…
Sure, please provide the text you would like me to summarize, and I'll be happy to help!
Precigen Advances in Gene Therapy Amidst Industry Developments Precigen, a leader in gene therapy and innovative biopharmaceuticals, continues to make strides in the field of healthcare as it focuses…
Precigen’s Pioneering Advances in Gene Therapy Precigen, a leader in the field of gene therapy, continues to make significant strides in the biopharmaceutical sector with its innovative approach to tr…
Pioneering Advances in RRP Treatment: Precigen’s PAPZIMEOS™ Shows Lasting Efficacy Precigen, Inc., a biopharmaceutical company dedicated to developing innovative precision medicines, presents promisin…
Pioneering Treatment for Recurrent Respiratory Papillomatosis Achieves Long-Term Success Precigen, Inc., a biopharmaceutical firm dedicated to advanced precision medicine, showcases significant advanc…
Precigen Engages Stakeholders in Upcoming Virtual Discussions on Innovative Therapy Precigen, Inc., a biopharmaceutical company committed to delivering innovative precision medicines, announces its pa…
Precigen Engages in Fireside Chats to Discuss Innovative Therapies for Respiratory Papillomatosis Precigen, Inc., a biopharmaceutical company known for its focus on precision medicine, announces its p…
### Precigen's Innovative Approach to Gene Therapy and Immunotherapy In the rapidly evolving field of biotechnology, Precigen is making significant strides with its innovative gene therapy and immunot…
Precigen Achieves Landmark FDA Approval for RRP Therapy Precigen, Inc. has reached a significant milestone with the U.S. Food and Drug Administration's (FDA) full approval of PAPZIMEOS™ (zopapogene im…
### Strategic Board Appointments Strengthen OS Therapies' Path to FDA Engagement OS Therapies, a clinical-stage biopharmaceutical company focused on immunotherapy and Antibody Drug Conjugates, enhance…